Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Orexo AB (ORXOY) reports developments for a Swedish pharmaceutical company whose U.S. security trades as ADRs on the OTCQX market. News centers on the company’s AmorphOX powder-based drug delivery technology, which is used to improve bioavailability and stability for small molecules, peptides and larger biomolecules, and on a diversified pipeline in clinical and preclinical development.
Recurring updates include R&D priorities following the U.S. Zubsolv divestment, organizational changes tied to product development, OX640 nasal epinephrine data for severe allergic reactions including anaphylaxis, intranasal formulation work with semaglutide, and collaborations for nasal powder vaccines. Company announcements also cover partner research, conference presentations and the parent company’s Nasdaq Stockholm listing alongside the ORXOY ADR program.
Orexo has announced a partnership with GoGoMeds to provide digital therapies, deprexis® for depression and vorvida® for alcohol misuse, making them available to those in need. Additionally, OXD01, aimed at treating opioid use disorder, will launch in the U.S. by Q4 2020. The COVID-19 pandemic has increased demand for such digital solutions. The therapies are designed to improve access to mental health care, utilizing AI for tailored content, and are accessible anytime, anywhere. This collaboration seeks to support various addiction services across the U.S.